Thienamycin non-producing mutants of Streptomydes cattleya were identified that displayed a cross-feeding relationship.
Thienamycin is one of the most potent, broad spectrum antibiotics presently known. It was the first discovered amonga series of naturally produced /Mactams which contain the carbapenem ring system1*. Elucidation of carbapenem biosynthesis lags behind that of the better known classes of /Mactams such as the penicillins and cephalosporins because of the technical difficulties associated with low titers and chemical instabilities. However, feeding studies with radiolabeled precursors have established the origin of all carbon atoms in the thienamycin molecule2). Both the C-8 and C-9 atoms in the hydroxyethyl side chain are derived from the S-methyl group ofmethionine. The same studies also showthat cystine, but not cysteamine or pantetheine, is incorporated into the cysteaminyl side chain (Fig. 1) . Based on these results, a biosynthetic pathway for thienamycin has been proposed3*. Streptomyces cattleya is one of only two species of Streptomyces knownto produce thienamycin4*.
In order to obtain more information about the thienamycin biosynthetic pathway, non-producing mutants of the wild type S. cattleya (ATCC 35852) were isolated by screening for lack, of growth inhibition zones on a lawn of indicator bacteria.
These mutants were characterized in the hopes of finding some which were blocked in the thienamycin biosynthetic pathway. One set of mutants showed an ordered pattern of cross-feeding and was selected for further study. Here weshow that one mutant of this set is deficient in the synthesis of a diffusible factor which, although structurally unrelated to thienamycin, is required for thienamycin biosynthesis. It does not appear to be an enzyme co factor, but may be an activator of transcription of one or more thienamycin biosynthesis genes.
Materials and Methods Characterization of Mutants and Cross-Feeding Assays Streptomyces cattleya MA4297was mutagenized with EMS(ethyl methanesulfonate). Colonies that did not produce thienamycin were identified by the failure to produce inhibition zones when plated on agar containing Staphylococcus aureus (ATCC6538p)5). Pairs of mutants were streaked in a T-pattern on SBLagar plates and overlaid with S. aureus to establish cross-feeding relationships which restored thienamycin production. Cross-feeding occurred when a mutant blocked at an early step in the pathway converted an intermediate produced by a mutant blocked late in the pathway, resulting in thienamycin production (Fig. 2) . Control experiments were performed to verify that the resulting inhibition zones were due to thienamycin production and not the result of other antibiotics produced by S. cattleya. As the result of such cross-feeding experiments, mutants RK-4 and RK-1 1 were selected for further study.
In a typical cross-feeding experiment in liquid medium, RK-4 and RK-1 1 mutants were grown for 24 hours in each of two seed media, and then transferred to synthetic production medium for 48 to 72hours3). Following three washes in 50mMNaPO4pH 6.5, each strain was resuspended to a 4x concentration in this buffer. This method was sufficient to prepare cells of the putative converter strain (RK-4) for cross-feeding. The putative producer strain (RK-1 1) was incubated an additio'nal 24 hours at 28°C and 220 rpm. Following this incubation, the RK-1 1 cells were centrifuged at 4,000 x g for 10minutes and the supernatant passed through a series of sterile filters (8.0~0.2jjm).
To evaluate cross-feeding, 125^1 of a fresh RK-4 resting cell suspension and 500//I of the filtered RK-ll supernatant were placed in sterile 16 x 125mmtest tubes and incubated overnight at 28°C and 220rpm. Cross-fed cultures were spun at 1,500 xg and 50^1 of the supernatant was placed on a paper antibiotic assay disc. After drying, the discs were transferred to a bioassay plate (24.5 cm x 24.5 cm x 2cm) prepared from 200 ml of LB agar containing 25 mg of 2,3,5-triphenyltetrazolium chloride (TTC) and seeded with 800 yul of an overnight S. aureus culture6). After overnight incubation at 37°C, successful cross-feeding produced clear, colorless zones of growth inhibition around the discs.
Isolation of RK-1 1 Product The RK-11 mutant was used to prepare a resting culture as described above3). After incubation as a resting culture for 24hours, the cells were spun at 16,000 x g for 10minutes, the pellet was discarded, and the supernatant was passed through a series of sterile filters (8.0~0.2^im). This filtrate was fractionated by reverse phase chromatography on Diaion HP-20 resin equilibrated with Milli-Q purified water. Fractions containing the RK-1 1 product were determined by the liquid cross-feeding assay described above. Active fractions from the column were pooled and concentrated by rotary evaporation. This concentrated pool was subjected to another round of HP-20 chromatography, after which fractions containing the RK-1 1 product were again identified by cross-feeding and S. aureus bioassay. The RK-ll product purified in this manner could then be used in radio-labeling studies or lyophilized for later HPLCanalysis.
Stability of Thienamycin and RK-1 1 Product and High Temperature and Alkaline pH
To test the stability of thienamycin at alkaline pH, the pH of a 500mMthienamycin stock solution was adjusted to 12.0 with NaOHand the solution immediately placed at 32°C. Upon addition of the NaOHand thereafter at 5 minute intervals, 25 fA aliquots were removed and placed in tubes containing 25 jn\ of 50 mMNaPO4buffer, pH 6.5 to neutralize the reactions. Contents of these tubes were later spotted onto discs and bioassayed on a S. aureus/TTC plate. After overnight incubation at 37°C, the size of the inhibition zones were measured. The amount of thienamycin present could then be estimated by comparison to a standard curve.
To test the stability of the RK-1 1 product, a 900//I aliquot was taken from a pool partially purified by HP-20 chromatography. The pH of this aliquot was adjusted to 12.0 with NaOHand the aliquot placed SEPT. 1994 at 32°C. At 5 minute intervals, 125fi\ samples were taken from the incubation tube and placed in tubes containing 125/d of 50mMNaPO4 buffer, pH 6.5, to neutralize the reactions. The tubes were stored on ice until all time points were taken. The contents of each tube were then cross-fed with a fresh 4x concentrated RK-4 resting cell suspension. After overnight incubation at 28°C and centrifugation, 50 fi\ aliquots of each cross-feed were assayed for antibiotic activity using the S. aureus/TTC bioassay. The amount of thienamycin was again estimated by measuring inhibition zone sizes.
Stability to Hydroxylamine
Following 2 rounds to HP-20 chromatography and lyoptimization, RK-1 1 product was resuspended in 240n\ 100him MOPSpH 7.0 plus 10jj\ 0.2m hydroxylamine-HC1 and allowed to incubate at room temperature for 30 minutes to determine its stability to hydroxylamine. After incubation, the sample was fractionated by HPLC(3.9 x 300mm C18 Resolve cartridge, mobile phase 10mMH3PO4-KH2PO4pH 3.5 at 1 ml/minute). As a reference, another portion of the same RK-ll batch was resuspended in 250/il 0.2m H3PO4-KH2PO4 buffer pH 3.05. After a 30minute incubation at room temperature, this sample was also resolved by HPLCusing the same column conditions. During HPLCof both samples, 1 ml fractions were collected into tubes containing 15/xl of 500mMK2PO4neutralizing buffer. From each fraction, a 500 fil aliquot was used for cross-feeding to 125 /xl of4 x concentrated RK-4 cells. After overnight incubation, 50 jj\ aliquots of these cross-fed cultures were assayed for antibiotic activity.
Precursor Incorporation Studies
In experiments to evaluate the incorporation of the knownthienamycin precursor, cystine, into the RK-1 1 product, a stock solution was prepared by dissolving 24mg L-cystine in 80ml of H2O and the pH was adjusted to 6.5 with 0.1 n NaOH.To this solution was added 46.2fid l-[35S]cystine giving a final concentration of 1.25mMcystine. Two 500ml baffled flasks each containing 40ml of 4 x concentrated RK-1 1 resting cells and 20ml of the cystine stock solution were incubated at 28°C and 220 rpm for 6 hours, after which another 20ml of the stock solution was added and incubation was continued for 18hours. The RK-1 1 product was partially purified by two cycles of HP-20 chromatography as described above. This partially purified product was cross-fed to a 4 x concentration of RK-4cells. After overnight incubation, the cells were spun at 16,000 x g for 10 minutes and the supernatant decanted. Following careful adjustment to pH 7.0 with 0.5m NH4OH, the supernatant was fractionated by Dowex anion exchange chromatography (HCO3-form, AG-X2; 50~100mesh)2). The column was washed with one volume of cold H2Oand the thienamycin was eluted with CO2-saturated H2O. Both absorbance at 297 nm and bioassays on S. aureusj TTCplates were used to determine the fractions containing thienamycin, which were then pooled and lyophilized. The lyophilized material was suspended in 10 mMKHPO4buffer and the thienamycin further purified by HPLC(8.9 x 300mm C18 Resolve column, mobile phase 10mM KHPO4at a flow rate of 1 ml/minute). One milliliter fractions were collected, and aliquots of each fraction were counted on a Beckmanliquid scintillation counter. Separate aliquots of each fraction were also tested for the presence of thienamycin using the S. aureus/TTC assay.
In another facet of the experiment, [35S]cystine was added to semipurified RK-1 1 product and this mixture was incubated overnight with RK-4 converter cells. The resulting thienamycin was partially purified by Dowex and HP-20 chromatographies, followed by fractionation by HPLCon Resolve C18. The HPLC fractions were both counted to determine [35S] content and bioassayed for antibiotic activity as described above.
In a parallel series of experiments to evaluate the incorporation of another known thienamycin precursor, methionine, into the RK-ll product, a stock solution was prepared by dissolving 162.5mg Several mutants of the Streptomyces cattleya strain MA4297were generated by EMStreatment and found to have cross-feeding relationships which restored antibiotic production as outlined in Fig. 2 . Of these mutants, RK-4 and RK-1 1 were selected for further investigation because they were prototrophic and retained the abilities to sporulate and produce cephamycin C. The product of cross-feeding RK-1 1 and RK-4 was demonstrated to be thienamycin (Fig. 3) . Upon analysis by HPLC, the bioactive product eluted under a peak corresponding to the sameabsorbance spectrum and retention time as authentic thienamycin. This bioactivity was also destroyed by incubation with porcine renal dehydropeptidase-1 (data not shown), as is thienamycin7). In addition, the RK-1 1 product was sensitive to hydroxylamine, as See text for explanation. Fig. 3 . Thienamycin production in a RK-1 1 cross-feeding experiment. A; A partially purified RK-ll product was incubated overnight with RK-4 cells. The resulting supernatant was analyzed by HPLCas described in Materials and Methods. Thienamycin was detected as a 297nm absorbing peak at 17.27 minutes. The corresponding photodiode array spectrum from 200~400 nm is shown. B; A comparable HPLCanalysis of a thienamycin standard is also shown. SEPT. 1994 is thienamycin, suggesting that the two might be related (Fig. 4) .
To determine whether these thienamycin non-producing mutants were blocked in thienamycin biosynthesis, we asked whether the RK-ll product could be labeled in vivo by feeding with [35S]cystine or [methyl-3H]methionine, both of which efficiently label thienamycin when added to wild type cultures3).
[35S]Cystine is incorporated into the cysteaminyl side chain, while [me^/-3H]methionine is the source or Dotn caroons 01 me nyaroxyieinyi siae cnain^rig.
1). In both labeling experiments, the RK-1 1 product was partially purified from the radiolabeled cultures in order to removeunincorporated aminoacid, and then the RK-ll product was added to a RK-4 culture. After overnight incubation, the resulting thienamycin was partially purified and analyzed for the extent of radioisotope incorporation. Thienamycinwas purified from the cross-feed supernatant as described in Fig. 5 and Materials and Methods. The radioactivity (A) and absorbance (B) profiles from HPLCare shown with bioactive fractions indicated by black bars. this case, substantial radioactivity copurified with the thienamycin (Fig. 6) , indicating that the conditions used can result in the production of labeled thienamycin. These data indicate that the RK-1 1 product does not contain a C-2 cysteaminyl side chain (Fig. 1) .
In the parallel feeding experiments with [rae%/-3H]methionine, RK-1 1 product was isolated from a labeled culture. Whenthis product was incubated with RK-4 cells and the resulting thienamycin was purified, no radiolabel was associated with it ( Fig. 7) . On the other hand, adding [rae%/-3H]methionine together with RK-1 1 culture supernatant to RK-4cells resulted in radiolabeled thienamycin (Fig. 8) .
Together, these data indicate that the RK-ll product contains neither the hydroxyethyl side chain nor Thienamycin was purified from the cross-feed supernatant as described in Fig. 5 and Materials and Methods. The radioactivity (A) and absorbance profiles from HPLC(B) are shown with bioactive fractions indicated by black bars. Table 1 . The effect of extremes of temperature and pH on thienamycin and RK-ll product.
(O) Thienamycin standards were incubated at 32°C and pH 12.0 for the amount of time indicated, then bioassayed on S. aureus/TTC plates, and the resulting inhibition zones measured, (a) Semi-purified RK-1 1 product was incubated at 32°C and pH 12.0 for the time intervals indicated. After neutralization, the solution was cross-fed to fresh RK-4cells. Thienamycin production was determined by inhibition zone sizes on S. aureus/TTC plates. a carbon moiety constructed by successive methylations, as would be expected of most thienamycin intermediates.
In further characterization of the RK-ll product, we have also shown that the RK-ll product is more stable to pHand temperature extremes than is thienamycin. Whenthienamycin is exposed to high temperatures (32°C) and pH 12.0, it rapidly degrades, losing it' s bioactivity (Table 1) . In contrast, when partially purified RK-1 1 product is exposed to the same extremes of temperature and pHand then incubated with RK-4cells, the ability to induce thienamycin production is more persistent (Table 1) . Since the simple carbapenem structure, as produced by Serratia and Erwinia species, is even less stable than thienamycin to these conditions8*, it is unlikely that the RK-1 1 product contains a bicyclic carbapenem ring structure minus the two side chains (Fig. 1) . In addition, the RK-ll product cannot be recovered from Dowexbicarbonate resin, a procedure that works well to purify thienamycin (data not shown). Since our data indicates that the RK-1 1 product is lacking a cysteaminyl side chain, a hydroxyethyl side chain, and the carbapenem ring structure, we conclude that the RK-11 product is neither structurally related to, nor a precursor of, thienamycin. Our data does indicate however, that the RK-1 1 product was able to stimulate de novo synthesis of thienamycin by RK-4cells.
Discussion
Wehave characterized a set of mutants and shown that they are deficient in the synthesis of a factor required for thienamycin biosynthesis. Evidence presented here indicates that this factor is not a precursor of thienamycin, nor does it appear to have any structural relationship to thienamycin. Attempts to purify the RK-1 1 product to the extent necessary for structure determination were hampered by a non quantitative assay and the poor chemical stability of the product. Thus, we have been unable to obtain structural data for this factor and can only speculate as to its nature. Onepossiblity is that it is a precursor to a vitamin or co factor required for an enzymein the thienamycin pathway. Although RK-4is not an auxotroph, suggesting it is not deficient in co factor synthesis, the availability and requirement for co factors may change during antibiotic production. We tested vitamin B12 and several other metabolites including pantetheine, biotin, and lipoic acid without finding any that induced RK-4 to produce thienamycin. Although unlikely, it is possible that the RK-1 1 product is a co factor specific for thienamycin biosynthesis.
Another possibility is that the RK-ll product could be a molecule that regulates expression of thienamycin biosynthetic genes or a precursor of such a molecule. There are several examples of small molecules that regulate secondary metabolism in Streptomyces and other microorganisms9). Recently, a homoserine lactone has been shownto regulate carbapenem production in Erwinia carotovora10). Wefound that there is a threshold above which further additions of purified RK-11 product to RK-4converter cells does not increase thienamycin production (data not shown), which is consistent with a regulatory function for the RK-1 1 product. Wetested two commercially available autoregulators, A-factor and nonalactone, neigher of which induced RK-4cells to produce thienamycin (data not shown). However, the structure of this potential regulator could be quite different.
It is curious that, of the manynon-producing mutants which cross-fed with other mutants to yield thienamycin, none have been shown to be blocked in the biosynthetic pathway. This appears to be in opposition to work with S. fulvoviridis where cross-feeding and complementation have been successful in establishing a set of mutants which are blocked in the biosynthetic pathways of the OA-6129 group of carbapenems11*. This suggests either that thienamycin is synthesized on a multifunctional complexand that the intermediates in the pathway are extremely labile, or that none of these intermediates are capable of diffusing between cells. More work on the biosynthetic pathway should resolve the question.
